The risks of using non-specific outcome measures to capture activities of daily living in myotonic dystrophy type 2 - Response

We appreciate the interest of Hamadeh et al in our study “How to capture activities of daily living in myotonic dystrophy type 2?” [1] and we thank for their valuable comments. This letter to the editor enriches the discussion of our study by highlighting the pitfalls and limitations of adopting Rasch-built scales developed for a specific disease, in another disease, even if these diseases share some common clinical features. We definetly agree, as stated in our conclusions, that a DM2-specific scale is the best option to monitor disease progression and response to therapy especially in the setting of clinical trials.
Source: Neuromuscular Disorders - Category: Neurology Authors: Tags: Letter to the Editor Source Type: research